Teriparatide vs Abaloparatide
How they differ
- FDA status, the same for both (FDA-approved). Teriparatide: FDA-approved as Forteo and other teriparatide products.1,2,3,4,5,6 Abaloparatide: FDA-approved as Tymlos for osteoporosis.7,8
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Teriparatide | Abaloparatide |
|---|---|---|
| What it is | Parathyroid hormone (1-34). The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same effects on bone and kidney.1 | A PTHrP(1-34) analogue that the label says acts on the PTH1 receptor and stimulates new bone formation.7 |
| FDA status | FDA-approved FDA-approved as Forteo and other teriparatide products1,2,3,4,5,6 FDA-approved. Drugs@FDA lists Forteo with an original approval date of November 26, 2002, and later teriparatide applications, the most recent approved on October 23, 2026. The cited label has no boxed warning.1,2,3,4,5,6 | FDA-approved FDA-approved as Tymlos for osteoporosis7,8 FDA-approved. Drugs@FDA lists Tymlos with an original approval date of April 28, 2017. The cited label has no boxed warning; its warnings include a risk of osteosarcoma seen in rats.7,8 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.9 | Not among the six peptides the policy lists.9 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 73 ClinicalTrials.gov records and 62 PubMed records collected | 9 ClinicalTrials.gov records and 33 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Teriparatide injection, solution · SPL version 10 · published 2026-09-21 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application ANDA214412 · original submission status AP · 2026-10-23 · dataset 2026-11-13 ↗
Drugs@FDA via openFDA · Official source · Source checked November 15, 2026
- 7TYMLOS (abaloparatide) injection, solution · SPL version 19 · published 2026-08-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 8Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 9HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026